Anti-HCV therapy with direct-acting antiviral agents in 5 long-term patients with long-term after liver transplantation
-
- HOSODA Kiyotaka
- Division of Transplant Surgery, Shinshu University Hospital
-
- MASUDA Yuichi
- Division of Transplant Surgery, Shinshu University Hospital
-
- KOYAMA Makoto
- Division of Transplant Surgery, Shinshu University Hospital
-
- OHNO Yasunari
- Division of Transplant Surgery, Shinshu University Hospital
-
- MITA Atsuyoshi
- Division of Transplant Surgery, Shinshu University Hospital
-
- URATA Koichi
- Division of Transplant Surgery, Shinshu University Hospital
-
- NAKAZAWA Yuichi
- Division of Transplant Surgery, Shinshu University Hospital
-
- KOBAYASHI Akira
- Division of Transplant Surgery, Shinshu University Hospital
-
- IKEGAMI Toshihiko
- Division of Transplant Surgery, Shinshu University Hospital
-
- MIYAGAWA Shin-ichi
- Division of Transplant Surgery, Shinshu University Hospital
Bibliographic Information
- Other Title
-
- C型肝炎に対する肝移植後長期経過症例に対する経口抗ウイルス薬療法の経験
Search this article
Abstract
<p>Liver cirrhosis resulting from the recurrence of hepatitis in patients with hepatitis C virus (HCV) is the major cause of graft loss after liver transplantation (LT). The effectiveness of treatment by direct-acting antiviral agents (DAAs) against HCV has been reported in LT patients. We report our experiences of anti-HCV therapy using DAAs in long-term HCV recipients. Five patients treated with DAAs were included in this study. Two patients were treated with pegylated-interferon (peg-IFN), ribavirin (RBV), and simeprevir (SMV), and three were with daclatasvir (DCV) and asunaprevir (ASV). All five had been previously treated with interferon (IFN) or peg-IFN with RBV after LT. Four of them discontinued antiviral therapy because of heart failure, retinal detachment, cellulitis, or diabetes mellitus. HCV reappearance was experienced after in the remaining patient who continued the therapy. In all patients, the levels of serum HCV-ribo nucleic acid were decreased to the under-detection level within 15 weeks; sustained virological response 24 weeks after treatment (SVR24) was then achieved. HCV could be eradicated with DAAs therapy even in long-term LT patients with failed IFN.</p>
Journal
-
- Japanese Journal of Transplantation
-
Japanese Journal of Transplantation 52 (1), 081-086, 2017
The Japan Society for Transplantation
- Tweet
Details 詳細情報について
-
- CRID
- 1390282680485970432
-
- NII Article ID
- 130005548926
-
- ISSN
- 21880034
- 05787947
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
- KAKEN
-
- Abstract License Flag
- Disallowed